Home > Pressrelease > Transcatheter Heart Valve Replacement Market size worth over $19.5bn by 2026

Transcatheter Heart Valve Replacement Market size worth over $19.5bn by 2026

  • Published Date: January 8, 2021

Transcatheter Heart Valve Replacement Market size is set to surpass USD 19.5 billion by 2026, according to a new research report by Global Market Insights Inc.

Rise in venture capital investments for transcatheter heart valve devices by major players in North America and Europe will stimulate the transcatheter heart valve replacement market growth. Several investors are engaged in investing in ventures owing to long-term growth perspective. For instance, Broadview Ventures in Boston promotes the development of technology for treatment and diagnosis of cardiovascular disease and stroke through direct equity-based investment. Broadview Ventures funds CardiAQ Valve Technologies’ Lifesciences domain that is focused on developing a percutaneous mitral valve technology. Moreover, 415 CAPITAL offers access to the European healthcare market by collaborating with CoRRect Medical GmbH that works on novel medical device technologies such as transcatheter aortic heart valve replacement and the world’s first stroke protection for left-heart interventions. Therefore, such venture capital investments are leading to development of novel heart valve replacement products. Increase in venture capital investment for transcatheter heart valve devices by major players such as Abbott and Medtronic are uplifting the market expansion.

Growing technological advancements in transcatheter heart valve replacement surgeries across Europe will spur the market revenue. Advancements in operative technique and critical care has reduced overall morbidity and mortality associated with surgical aortic valve replacement. Bioprosthetic valve fracture (BVF) has been established as a safe and effective method to facilitate valve-in-valve TAVR that includes fracture of surgical valve ring with high-pressure balloon inflation. The technique enables more optimal THV expansion with significant improvement in postprocedural gradients. Transaxillary, suprasternal approach and transcaval approaches are being considered as alternatives for transfemoral approach for patients with the non-accessible femoral artery. Medtronic released its recapturable, self-expanding CoreValve Evolut R System that enables wider use of transfemoral access route. Furthermore, researchers are focusing on new laceration techniques including leaflet laceration to split valve leaflets that could assist in TAVR surgery. These advancements will uplift the number of patients opting for TAVR procedures.

Rise in demand for transcatheter aortic valve replacement will boost the transcatheter heart valve replacement market value

Transcatheter Heart Valve Replacement Market

Get more details on this report - Request Free Sample PDF

Transcatheter aortic valve replacement segment valued at more than USD 4.94 billion in 2019 due to the prevalence of aortic valvular disease. According to a published study of 2020, the prevalence of aortic stenosis was around 12.4% in the U.S., Europe and Taiwan. The increasing prevalence of aortic stenosis is driving the demand for transcatheter aortic valve. Transcatheter aortic valve replacement (TAVR) is a safe and feasible alternative treatment for patients with severe aortic stenosis (AS) that are at high risk for surgical aortic valve (AV) replacement. Large randomized clinical trials have proven TAVR to be superior to medical therapy in patients considered inoperable. 

Browse key industry insights spread across 250 pages with 430 market data tables & 18 figures & charts from the report, “Transcatheter Heart Valve Replacement Market Size By Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Repair and Replacement, Transcatheter Pulmonary Valve Replacement), By Surgical Approach (Transfemoral Approach, Transapical Approach), By Application (Aortic Valvular Heart Disease {Aortic Valve Stenosis, Aortic Valve Regurgitation}, Mitral Valvular Heart Disease {Mitral Valve Stenosis, Mitral Valve Regurgitation}, Pulmonary Valvular Heart Disease) By End-use (Hospitals, Cath Labs), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026” in detail along with the table of contents:

Growing preference for transfemoral approach will enhance the market demand

Transfemoral approach segment in the transcatheter heart valve replacement market exceeded USD 4.52 billion in 2019 led by the preference for minimally invasive procedures. Presently, transfemoral approach is the most used approach worldwide as it reduces complication rates in TAVR procedures. In addition, transfemoral TAVI offers fully percutaneous procedure performed under local anesthesia with mild sedation via a puncture of the common femoral artery. Rapid technological advancements in transcatheter aortic valve replacement is augmenting the number of patients preferring transfemoral approach. 

Increasing prevalence of pulmonary valvular heart disease will foster the market growth

Pulmonary valvular heart disease application segment in the transcatheter heart valve replacement market crossed USD 599 million in 2019 propelled by the growing prevalence of pulmonary valvular heart disease in pediatric population. Infants are majorly prone to pulmonary valvular stenosis and are needed to undergo transcatheter aortic valve replacement. In some patients, pulmonary valvular heart disease is congenital. Thus, this factor has impacted the utilization of transcatheter aortic valves. 

Growing patient inflow in catheterization labs will impel the industry growth

Transcatheter heart valve replacement market for Cath labs end-use segment is expected to witness around 21.6% growth rate till 2026. The patient inflow in Cath labs is increasing owing to the growing incidences of cardiovascular disorders. As a result, there is a significant rise in number of transcatheter heart valve replacement procedures in catheterization labs. Emergence of COVID-19 is also compelling people to prefer catheterization labs in order to avoid exposure to patients in other healthcare settings, thereby contributing to the increased number of cardiovascular procedures. These factors are potentially uplifting the demand for transcatheter heart valve replacement in Cath labs. 

Rising prevalence of aortic valvular disorders in China is anticipated to fuel the regional growth

China transcatheter heart valve replacement market is projected to expand at 67.2% CAGR during 2020 to 2026 on account of the growing incidences of aortic valvular disease (AVD). Bicuspid aortic valve disorder is a common disorder in China with a prevalence of around 50% in patients suffering from severe aortic stenosis. Therefore, the number of people undergoing TAVR procedures in the country is increasing that is creating a consistent demand for transcatheter aortic valves. The application of transcatheter aortic valve implantation is in the early stages of testing in China, particularly for the balloon-expandable valve procedure. As a result, several transcatheter heart valve replacement products have been approved in the country in recent years, thereby contributing to the market expansion. 

Companies are focusing on strategies and launch of innovative products to expand customer base

Some of the major players operating in the transcatheter heart valve replacement market are 4C Medical Technologies, Abbott, Boston Scientific, Edwards Lifesciences, HighLife Medical, JC Medical, LivaNova, Medtronic plc, and Neovasc among others. These companies are proposing innovative product launches in order to generate significant revenue in the market and increase their geographical presence. 


Authors: Sumant Ugalmugle, Ajay Devgire